Introduction {#S1}
============

Cancer is among the top killer diseases and has emerged as a major public health problem around the world, and it will still be the main cause of the morbidity and mortality during the next few decades ([@B1]). Bray et al. estimated that the incidence of all cancer cases would up to 22.2 million in 2030 ([@B2]). In order to cure cancer, researchers have tried many antitumor strategies, but the recurrence and mortality rate of cancer are still high. Adoptive immunotherapy, as an adjuvant or alternative treatment, holds great promise in treating various malignant tumors. Cytokine-induced killer (CIK) cells are considered to be an ideal candidate cell type for cancer immunotherapy. A lot of basic researches and clinical studies show the safety and feasibility of CIK therapy in treating malignant tumors. Combination of CIK with either immunological or genetic engineering approaches have been made to improve the effects of CIK and all the key events in the history of CIK immunotherapy are shown in Figure [1](#F1){ref-type="fig"} ([@B3]--[@B16]). In this review, the research progress and clinical application of CIK are summarized.

![Selected highlights in the development of immunotherapy.](fimmu-08-00774-g001){#F1}

What is CIK? {#S2}
============

Cytokine-induced killer cells were first discovered in 1991 ([@B5]) and are a heterogeneous population of CD8^+^ T cells, which were generated from human peripheral blood lymphocytes (PBLs) and simply expanded *ex vivo via* incubation with an anti-CD3 antibody, interferon-γ (IFN-γ), and interleukin (IL)-2. They can kill tumor cells mediated by FasL and perforin ([@B17]). According to the presence of cell surface molecule CD56, CIK cells are also divided into two main subsets: CD3^+^CD56^+^ T cells and CD3^+^CD56^−^ T cells ([@B18]). CD3^+^CD56^+^ T cells, which are also called the natural killer T cells, are considered to be the major effector cells of CIK. So, CIK cells can lyse cancer cells in a MHC-unrestricted manner through activating NK cell receptors such as DNAX accessory molecule-1, NKp46, NKG2D, and NKp30 ([@B11], [@B19], [@B20]). In addition to the direct killing effect of CIK on cancer cells, they can also regulate the immune function by secreting various cytokines. A lot of studies have indicated that after stimulation by tumor cells, the levels of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, IFN-γ, and IL-2 secreted by CIK cells are significantly upregulated ([@B21]), and these cytokines further enhance systemic antitumor activity and induce a Th1 immune response.

*Ex Vivo* Expansion and Alloreactivity of CIK Cells {#S3}
===================================================

Obtaining a sufficient number of antitumor immune cells is a critical step in the successful application of CIK cell immunotherapy ([@B22]). Fortunately, CIK cells can be easily expanded *in vitro* from peripheral blood mononuclear cells (PBMC), and some reports also showed that they could be also generated from umbilical cord blood precursors or bone marrow ([@B23], [@B24]). The general culture protocol for the *ex vivo* expansion of CIK cells requires 3--4 weeks with the addition of IFN-γ, anti-CD3 antibody, and IL-2. And the detail steps are as follows: on day 0, the PBMC are separated by density-gradient centrifugation from the whole blood ([@B24], [@B25]) and treated with IFN-γ to activate macrophages, which further provide cytokine-mediated (IL-12) and contact-dependent (CD58/LFA-3) signals to promote the cytotoxic power of CIK cells ([@B26]--[@B28]). On day 1, anti-CD3 antibody and IL-2 are added to the medium. Anti-CD3 will provide mitogenic signals for T cells which are then sustained by the continuous presence of IL-2 ([@B29], [@B30]). Fresh medium with IL-2 is added every 2 days. After 3--4 weeks of culture, the generated CIK cells are subsequently infused back into patients (Figure [2](#F2){ref-type="fig"}). The amount of injected CIK cells varied in different studies, so did the cell expansion rates. In fact, the average final expansion rates were usually in a range of 100-fold, but individual expansion rate was described to be variable from few to more than 1,000-fold ([@B5], [@B25], [@B31], [@B32]). It is well known that the more the CIK cells are injected and expanded, the better they response. Hontscha et al. showed that the total number of injected CIK cells ranged from 21.9 × 10^7^ to 5.2 × 10^10^ ([@B14]), Li et al. found the total number of CIK cells ranged from 6 × 10^6^ to 1.5 × 10^10^ in Chinese clinical trials ([@B33]). Until now, the least injected number of CIK cells was reported to be 6 × 10^6^ to obtain an objective response. Cohen et al. considered that tumor-infiltrating lymphocytes (TILs) must be expanded to 10^10^ for a successful treatment ([@B34]). Therefore, \~10^10^ CIK cells might be a good choice and many studies used more than 1 × 10^10^ cells to transfuse into the patients. As mentioned above, the reason why CIK expansion rate varies greatly is unclear. But there are still some additional strategies under investigation to further improve the expansion of CIK cells ([@B22]), which include adding new cytokines to the culture medium, such as IL-1, IL-7, IL-15, or thymoglobulin ([@B8], [@B35], [@B36]).

![*Ex vivo* expansion of cytokine-induced killer cells and infusion.](fimmu-08-00774-g002){#F2}

Cytokine-induced killer immunotherapy, a personalized therapy that uses patients' own PBMC to expand antitumor CIK cells which are then reinjected into patients themselves, rarely causes autoimmune response. But sometimes, it is very difficult to obtain a sufficient number of CIK cells due to the poor health situation of patients, such as elderly people and patients with immunodeficiency diseases ([@B37]). To solve this problem, getting CIK cells from donor PBMC seems to be an alternative option. Studies showed that CIK cells exhibited a decreased alloreactivity across HLA barriers that could further reduce the risk of graft-versus-host disease (GVHD). Many phase I clinical studies proved that infusion of the allogeneic CIK cells in patients relapsing after allogeneic hematopoietic cell transplant would reduce the incidence of GVHD events ([@B38]--[@B40]). Another solution to obtain sufficient CIK cells is collecting from the cord blood. Mature protocols have already been made for generation of cord blood-derived CIK (CB-CIK) cells ([@B41]). The CB-CIK cells displayed relatively lower expression of HLA, indicating a weaker immunogenicity and lower risk of GVHD ([@B42]). Many clinical trials proved that CB-CIK cells were effective and safe to patients with malignancies ([@B43], [@B44]). All these suggest that CIK is a safe immune therapy with lower risk of GVHD.

Improved CIK Therapy {#S4}
====================

In the last decade, CIK cells have begun to be used in clinical care with good prospects for treatment success, and a great deal of research has been done to improve their cytotoxicity and safety. Here, we have summarized the current improved CIK therapies (Figure [3](#F3){ref-type="fig"}) ([@B45], [@B46]).

![A schematic picture showed the improved CIK therapy. CIK, cytokine-induced killer; TA, tumor antigen; CAR, chimeric antigen receptor; Bis-Ab, bispecific antibody; Ab, antibody; DC, dendritic cells.](fimmu-08-00774-g003){#F3}

CIK Combined with Additional Cytokines {#S4-1}
--------------------------------------

Cytokine-induced killer cells are a heterogeneous cell population that can be expanded *ex vivo* from PBMC with the addition of IFN-γ, anti-CD3 antibody, and IL-2. In fact, many additional cytokines have been made to improve CIK antitumor activity. These cytokines can improve cell proliferation and cytotoxicity partly by suppressing the generation of regulatory T (Treg) cells that are known to inhibit antitumor immunity.

Lu et al. reported a new protocol for expansion of highly efficient cytotoxic CIK cells by culturing PBLs with addition of IL-1α ([@B23]). Another research showed that addition of IL-6 could significantly decrease the percentage of Treg cells and simultaneously increase the proliferation ability and cytotoxicity of the CIK cells against hepatocellular carcinoma (HCC) *in vitro* ([@B47]). By transfecting IL-7 gene expression vector into CIK cells, Finke et al. demonstrated an improved proliferation rate and enhanced antitumor cytotoxicity of CIK cells ([@B48]). Further study showed an upregulation of LFA-1 (CD11a/CD18) and CD28 in CIK cells with the addition of exogenous IL-7, which were essential for cytotoxic activity of CIK and played an important costimulatory role in T cell activation, respectively ([@B49]).

As an immune stimulatory cytokine, IL-12 has the strongest antitumor activity that can induce a Thl type of response and active NK and cytotoxic T lymphocyte (CTL) cells ([@B50]). CIK cells, generated with exogenous IL-12 instead of IL-2, showed similar cytotoxicity ([@B8]). However, due to its high toxicity, a lower dose of IL-12 should be used in combination with CIK in clinical application ([@B50]). Many studies demonstrated that CIK cells stimulated with IL-15 displayed improved proliferation capacity and cell cytotoxicity against hematologic and solid malignancies ([@B36], [@B51]--[@B55]). And a possible mechanism for its function might be the regulation of Treg cells and the expression of toll-like receptor 4, Wnt 4, PDGFD, and IL-35 ([@B51], [@B56], [@B57]). Application of IL-21 did not increase the proliferation rate of CIK cells ([@B58], [@B59]), but the cell cytotoxicity was significantly enhanced by increasing expression of IFN-γ, TNF-α, perforin, and granzyme B.

Dendritic Cell (DC)--CIK {#S4-2}
------------------------

Dendritic cells are professional antigen-presenting cells (APCs) that can capture and process tumor-associated antigens (TAAs) ([@B60]). Given their particular ability to stimulate both adaptive and innate antitumor immune responses, DCs have been used as a powerful pharmacological tool for cancer immunotherapy ([@B61]). Many researches showed that DCs could promote NK cell-dependent antitumor effects through a cell-to-cell contact ([@B62], [@B63]). In recent years, studies have focused on the combinational treatment of DCs and CIK cells and proved a relative more safe and effective therapeutic effect on advanced solid carcinoma, which provide a new and efficacious immunity therapeutic strategy for cancer treatment. Cao et al. showed that coculture of CIK cells with DCs *in vitro* could improve the proliferation rate and antitumor activity of CIK cells ([@B64]). Further studies showed that the cellular interactions between CIK cells and DCs led to changes in the surface molecule expression of both populations and a significant increase of IL-12 secretion, and finally resulted in a higher cytotoxic activity of CIK cells ([@B10]). Pan et al. reported that DCs decreased the concomitant expanded Tregs in CIK cells and enhanced the cytotoxicity of CIK cells against leukemia cells ([@B65]). As we all know, delivering TAAs to DCs as vaccines have been reported to be an effective strategy for the treatment of various advanced malignancies. The combination of DCs vaccination with CIK cells is considered to be more prospected, and studies showed a significantly stronger antitumor activity and fewer side effects ([@B17], [@B66]--[@B69]). Jung et al. showed that in an *in vivo* animal model, the CIK + DC vaccination therapy was more effective than CIK or DC vaccination alone therapy for the treatment of hepatocarcinoma tumor cells ([@B70]). More recently, Lin et al. reported that DC--CIK therapy could improve survival by reducing the risk of disease progression in stage IV breast cancer patients ([@B71]).

CIK Combined with Immune Checkpoint Inhibitors {#S4-3}
----------------------------------------------

Immune checkpoints are molecules that can either turn up or turn down signals in immune system. When CTLs recognize and trigger tumor cell death by inducing apoptosis, various checkpoint pathways between APCs/tumor cells and T cells are activated to provide signals for T cell activation ([@B72], [@B73]). There are at least two signaling pathways regulating the activation or inhibition of the CTLs: the primary signal is the binding occurred between peptide--MHC which is presented by APCs and T cell receptors. The secondary signal is the costimulatory/coinhibitory signal that regulates T cell activation ([@B74], [@B75]). The CD28, OX40, CD58, CD40L, CD80, CD86, and CD137 are stimulators that can promote immune activation, whereas programmed death 1 (PD-1), cytotoxic lymphocyte-associated antigen 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), T cell immunoreceptor with Ig and ITIM domains, and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) are inhibitors that suppress immune activation. CTLA-4 and PD-1 involved in the T-cell immune evasion in many malignancies, thus they are always designed as targets for cancer immune therapies ([@B16], [@B76]). It has been demonstrated that the blockade of inhibitory receptors such as PD-1, KIR, TIM-3, and LAG-3 but not CTLA-4 on CIK cells can significantly increase their antitumor potency against hematological malignancies. However, the combination of inhibitors against two receptors showed no increased cytotoxicity compared to that of one alone ([@B77]). Dai et al. reported that the blockade of PD-L1/PD-1 augmented CIK cytotoxicity against gastric and colorectal cancer cells. Additionally, combined therapy of CIK with checkpoint inhibitors (PD-L1/PD-1 blockade) could inhibit tumor growth and prolong the survival in the murine model of gastric cancer compared to untreated mice ([@B16]). All these suggest that combination of CIK cells with checkpoint inhibitors will be a novel immunotherapy for cancer treatment.

CIK Combined with Antibodies {#S4-4}
----------------------------

Immunotherapy of tumors with specific antibodies has been established as one of the most successful therapeutic strategies in the last 20 years. The mechanisms of antibody-based tumor cell killing are as follows: (1) antibody can directly bind to the cell surface receptor, deliver drug or toxin to target tumor cells, induce cell apoptosis, and reduce proliferation; (2) antibody can kill tumor cells by immune-mediated killing mechanisms such as activating complement, antibody-dependent cellular cytotoxicity, and regulating T cell function; (3) antibody can regulate tumor angiogenesis by vasculature receptor antagonism or ligand trapping ([@B78], [@B79]). Many studies showed that CIK cells combined with antibody could improve their cytolytic activity. Pievani et al. reported that addition of anti-CD20 mAb rituximab or GA101 could significantly enhance cytotoxicity of CIK cells to B-cell lymphoma *in vitro* ([@B20]). Deng et al. further proved that the enhanced CIK cytotoxicity induced by anti-CD20 mAb was partly related to the increased expression of components of the MAPK/ERK and STAT signaling pathways ([@B80]). Esser et al. reported that the combinational treatment of CIK cells with anti-CD30 mAb Brentuximab Vedotin (SGN-35) achieved better efficacy in CD30^+^ lymphoma, and SGN-35 did not affect the function of CIK cells ([@B81]). Besides, bispecific antibodies (BsAbs) that have two different antigen-binding sites could improve adoptive immunotherapy effect by cross-linking CIK cells with malignant tumor cells ([@B82]). BsAb CD19 × CD5 (HD37 × T5.16) has been reported to increase the cytolytic activity of CIK cells against B-lymphoma cells ([@B83]). BsAbs against cancer antigen-125 and Her2 significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer in both *in vitro* and *in vivo* models ([@B84]). BsAb EGFR/CD3 could improve the cytotoxic activity of CIK cells toward gastric cancer cells ([@B85]). When combined with anti-CD3/anti-CD133 BsAb, CIK cells showed significantly stronger cytotoxicity to CD133^high^ pancreatic and hepatic cancer cells than that of CIK, CD3-CIK, or BsAb alone ([@B86]). Recently, Ma et al. reported that CIK cells armed with BsAb CD3 × EGFR (EGFRBi-Ab) to target EGFR-positive glioblastoma significantly increased CIK cells cytotoxic activity *in vitro* and inhibited the growth of glioblastoma tumors in glioblastoma xenograft mice ([@B87]). All these data suggest a better *in vitro* and *in vivo* antitumor effect of CIK cells combined with antibodies, which will definitely provide a novel useful method for the CIK cells.

CIK Combined with Chimeric Antigen Receptor (CAR) {#S4-5}
-------------------------------------------------

To promote target cell recognition and improve specific cytotoxicity of CIK, CIK cells are always engineered with a CAR that is targeted to specific antigen. CIK cells engineered with a CAR that was directly targeted against carcino-embryonic antigen (CEA) showed improved activation toward CEA^+^ colon carcinoma cells, compared to that of CEA^−^ cells ([@B15]). Oelsner et al. proved that CD19 CAR-engineered CIK cells could dramatically enhance their antileukemic activity ([@B88]). Remarkably, Marin et al. found that CIK cells combined with CD19-target CARs containing a costimulatory CD28 or 4-1BB domain together with CD3ζ exhibited better antitumor effect than CARs based on DAP10 or CD3ζ alone ([@B89], [@B90]). Likewise, Hombach et al. reported that CIK cells arming with CD28-CD3ζ CAR showed stronger cytotoxicity; however, CIK cells arming with the third-generation CD28-CD3ζ-OX40 CAR that provided a super costimulation signal exhibited less antitumor efficacy due to increased activation-induced cell death ([@B91]). All these data indicate that CIK cells modified by CAR have stronger tumor cell killing activity, and the appropriate design for CAR is crucial for the successful application of CAR-mediated CIK response.

CIK Combined with Chemotherapy {#S4-6}
------------------------------

Many studies have shown that CIK/DC--CIK combined with different chemotherapy regimens for cancer treatment exhibited better efficacy than chemotherapy alone. Wu et al. showed that CIK cells plus chemotherapy (docetaxel and cisplatin) could significantly prolong the progression-free survival (PFS) and overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients ([@B92]). Niu et al. proved that CB-CIK cells combined with second-line chemotherapy drug (dexamethasone) could improve PFS and OS in patients with advanced solid malignancies after first-line chemotherapy failure ([@B44]). As we all know, chemoresistance is a major problem to be solved in the treatment of cancers. Interestingly, many studies showed that the combination of CIK with chemotherapy could overcome chemotherapy resistance by activating the immune system ([@B93], [@B94]). Zheng and Han analyzed the efficiency and safety of chemotherapy combined DC with CIK cells in the treatment of NSCLC using meta-analysis. They found that chemotherapy combined with DC--CIK immunotherapy was superior in 1-year OS, disease control rate (DCR), and disease-free survival (DFS). Meanwhile, no more adverse events (AEs) appeared. However, there was no obvious improvement in objective response rate (ORR), partial response, 2-year PFS, and OS. All these suggested the combination therapy was modest in efficacy and safer for advanced NSCLC patients ([@B95], [@B96]). Similar results, with significantly prolonged 1--5 year OS, DFS, and improved DFS, ORR, and DCR with the infusion of CIK/DC--CIK combined with chemotherapy was reported by Mu et al. in patients with gastric cancer. Moreover, the levels of IFN-γ and IL-12, except IL-2, significantly increased after CIK/DC--CIK therapy, proving that the immune function of gastric cancer patients also significantly improved ([@B97]). Another meta-analysis proved that DC--CIK combined with chemotherapy could prolong 1-year OS, 2-year OS, and 3-year OS on colon cancer ([@B98]). All these data indicate an antitumor effect of CIK and chemotherapy in comparison with the use of chemodrugs or CIK cells alone.

CIK Combined with Nanomedicine {#S4-7}
------------------------------

With the rapid development of nanotechnology and nanomedicine, nanomaterials have been applied in various fields, especially in human health care. In recent years, nanotechnology has brought many new methods for cancer treatment ([@B99]--[@B103]). Nanometer-sized particles (1--100 nm) are in the same range of dimension as biomacromolecules including antibodies and membrane receptors ([@B104]). Their inherent physical/chemical properties or being loaded with different imaging/therapeutic agents in their surface, all of which make nanoparticles become a powerful tool for diagnosis, imaging, and therapy ([@B105]--[@B107]). Importantly, nanomaterials with low toxicity can be used as vaccine carrier/adjuvant to improve the immunogenicity of antigens by enhancing their cellular uptake, preventing enzyme degradation, and regulating the immune cells function ([@B108], [@B109]). Many researchers explored the potential applications of nanomaterials in monitoring the trafficking of DCs and enhancing the efficacy of DC-based cancer vaccines, such as quantum dots ([@B110]), magnetic nanoparticles ([@B111]--[@B114]), and upconversion nanoparticles ([@B115]). Furthermore, it has been reported that nanoparticles could also work as cancer vaccines ([@B116]), and these cancer nanovaccines could be envisioned as nanocarriers codelivering antigens and adjuvants ([@B117]--[@B119]). As we discussed, the efficacy of DC--CIK is better than DC or CIK alone, so we propose that the combination of CIK/DC--CIK cells with nanomaterials may have a great potential in cancer immunotherapy.

Clinical Trials on CIK Cells {#S5}
============================

At present, CIK as a pharmacological tool for cancer therapy has been tested in clinical trials of various tumors. 90 registered clinical trials have been found on the website [ClinicalTrials.gov](ClinicalTrials.gov) (<http://www.clinicaltrials.gov>) (Table [1](#T1){ref-type="table"}) by searching the keywords: cytokine-induced killer cells or CIK. One trial is working on psoriasis (Table [1](#T1){ref-type="table"}). The majority of these are concentrated in China (58 studies), followed by 6 studies in U.S., 3 studies in Singapore, and 3 studies in Korea. Besides, two trials (NCT01533727, NCT02539017) have been withdrawn, 1 trial terminated (NCT01871480), 22 trials have been completed. Below, we will summarize these clinical trials on CIK cells.

###### 

Clinical studies on cytokine-induced killer (CIK) cells.

  Trial         Phases      Experimental design                             Target disease                                    Recruitment              Enrollment
  ------------- ----------- ----------------------------------------------- ------------------------------------------------- ------------------------ ------------
  NCT01533727   II          CIK + chemotherapy                              Non-small-cell lung cancer (NSCLC)                Withdrawn                0
  NCT02539017   II          Dendritic cell (DC)/CIK + chemotherapy          Triple-negative breast neoplasms                  Withdrawn                0
  NCT01871480   II          CIK + gefitinib                                 NSCLC                                             Terminated               50
  NCT01655628   II          CIK + chemotherapy                              Nasopharyngeal carcinoma                          Recruiting               40
  NCT01902875   Undefined   CIK + chemotherapy                              NSCLC                                             Recruiting               100
  NCT01914263   I           CIK                                             Solid tumor                                       Recruiting               40
  NCT01868490   I/II        CIK                                             Cholangiocarcinoma                                Recruiting               13
  NCT01186809   II          CIK                                             Hematologic malignancies                          Recruiting               50
  NCT01839539   II          DC--CIK                                         Colorectal cancer                                 Recruiting               60
  NCT01799083   I/II        Decitabine + CIK                                Solid tumors/B cell lymphoma                      Recruiting               100
  NCT00862303   I/II        DC--CIK                                         Renal cell carcinoma                              Recruiting               100
  NCT02621333   II          CIK + chemotherapy                              Lung adenocarcinoma                               Recruiting               280
  NCT02280278   III         Radical surgery/adjuvant chemotherapy + CIK     Colon cancer                                      Recruiting               550
  NCT01592422   II          CIK                                             Small-cell lung cancer                            Recruiting               60
  NCT01498055   II/III      CIK                                             Lung cancer                                       Recruiting               120
  NCT01481259   II/III      CIK                                             NSCLC                                             Recruiting               120
  NCT02752243   I/II        CIK                                             Myelodysplastic syndromes (MDSs)/acute leukemia   Recruiting               40
  NCT02651441   I/II        DC--CIK + chemotherapy                          NSCLC                                             Recruiting               60
  NCT02568748   III         CIK                                             Advanced HCC                                      Recruiting               20
  NCT02487017   II          DC--CIK + TACE                                  Hepatocellular carcinoma (HCC)                    Recruiting               60
  NCT02644863   II          DC--CIK + chemotherapy                          Esophageal cancer                                 Recruiting               60
  NCT01691625   Undefined   DC--CIK                                         Esophageal cancer                                 Recruiting               50
  NCT01758679   IV          Licartin + CIK                                  HCC                                               Recruiting               120
  NCT01783951   I/II        S-1 + DC--CIK                                   Gastric cancer                                    Recruiting               30
  NCT01781520   I/II        S-1 + DC--CIK                                   Pancreatic cancer                                 Recruiting               30
  NCT02504229   II          DC--CIK + chemotherapy                          Gastric cancer                                    Recruiting               80
  NCT01691664   Undefined   Radiation therapy + DC--CIK                     Esophageal cancer                                 Recruiting               40
  NCT01884168   Undefined   DC--CIK                                         Malignant tumor                                   Recruiting               30
  NCT01898793   I           Chemotherapy + CIK                              Leukemia, myeloid, acute                          Recruiting               24
  NCT01906632   Undefined   DC--CIK                                         Malignant tumor                                   Recruiting               50
  NCT02851784   II/III      Microwave ablation + CIK                        HCC                                               Recruiting               50
  NCT01929499   II          CIK                                             Colonic neoplasms                                 Not yet recruiting       210
  NCT01821495   II          DC--CIK to treat NPC                            Nasopharyngeal carcinoma                          Not yet recruiting       100
  NCT02496988   IV          Temozolomide + CIK                              Advanced milignant gliomas                        Not yet recruiting       120
  NCT02494804   I/II        Temozolomide + CIK                              Milignant gliomas                                 Not yet recruiting       80
  NCT02490735   II          CIK                                             Esophageal squamous cell carcinoma                Not yet recruiting       2,000
  NCT01631357   II/III      CIK + chemotherapy                              Lung cancer                                       Not yet recruiting       200
  NCT01821482   II          DC--CIK                                         HCC                                               Not yet recruiting       100
  NCT02497898   II          CIK                                             Lymphoma, non-Hodgkin                             Not yet recruiting       1,000
  NCT02487550   II          DC--CIK                                         Renal neoplasma                                   Not yet recruiting       1,200
  NCT01235845   I/II        DC-activated CIK + DC                           Malignant glioma                                  Not yet recruiting       30
  NCT02415699   II/III      DC--CIK + chemotherapy                          Colorectal cancer                                 Not yet recruiting       100
  NCT01240005   I/II        DC--CIK                                         Renal cell carcinoma                              Not yet recruiting       30
  NCT01828008   Undefined   CD20 antibody + CIK                             Lymphomas                                         Not yet recruiting       20
  NCT02688686   I/II        Genetically modified DC + CIK                   NSCLC with bone metastases                        Not yet recruiting       30
  NCT02498756   II          CIK + ipilimumab                                Melanoma                                          Not yet recruiting       300
  NCT02585908   I/II        CIK + γδ T                                      Gastric cancer                                    Not yet recruiting       120
  NCT02856815   II          CIK                                             Hepatocellular                                    Not yet recruiting       78
  NCT02782546   II          CIML NK cell                                    Acute myeloid leukemia                            Not yet recruiting       60
  NCT00769106   III         CIK                                             HCC                                               Completed                200
  NCT02419677   II/III      Radiofrequency ablation + CIK                   Colorectal cancer                                 Completed                60
  NCT00815321   II          CIK                                             Chronic myeloid leukemia                          Completed                11
  NCT00394381   I/II        CIK                                             Acute myeloid leukemia/MDS                        Completed                17
  NCT01749865   III         CIK                                             Carcinoma, hepatocellular                         Completed                200
  NCT00460694   I/II        CIK                                             Hematological malignancies                        Completed                24
  NCT00477035   I/II        CIK                                             Hematologic malignancies                          Completed                22
  NCT01232062   Undefined   DC--CIK + chemotherapy                          Triple-negative breast cancer                     Completed                46
  NCT02406846   Undefined   DC--CIK + cryosurgery                           Neoplastic cells, circulating                     Completed                80
  NCT02412384   Undefined   DC--CIK + cryosurgery                           Neoplastic cells, circulating                     Completed                120
  NCT02450448   Undefined   DC--CIK + cryosurgery                           Neoplastic cells, circulating                     Completed                60
  NCT02416635   Undefined   DC--CIK + cryosurgery                           Neoplastic cells, circulating                     Completed                60
  NCT02450357   Undefined   DC--CIK + cryosurgery                           Neoplastic cells, circulating                     Completed                60
  NCT02450435   Undefined   DC--CIK + cryosurgery                           Neoplastic cells, circulating                     Completed                60
  NCT02450422   Undefined   DC--CIK + cryosurgery                           Neoplastic cells, circulating                     Completed                60
  NCT02425735   I/II        DC--CIK + γδ T                                  Liver cancer                                      Completed                40
  NCT00807027   III         CIK + chemotherapy                              Glioblastoma                                      Completed                180
  NCT01395056   Undefined   DC--CIK + chemotherapy                          Triple-negative breast cancer                     Completed                23
  NCT02425748   I/II        DC--CIK + γδ T                                  Lung cancer                                       Completed                40
  NCT02418481   I/II        DC--CIK + γδ T                                  Breast cancer                                     Completed                40
  NCT00699816   III         CIK                                             Hepatocelluar carcinoma                           Completed                230
  NCT00186342   Undefined   CIK                                             Hematologic malignancies                          Completed                120
  NCT02482454   II/III      Radiofrequency ablation + CIK                   Cholangiocarcinoma                                Active, not recruiting   50
  NCT01392989   II          CIK + chemotherapy                              MDSs                                              Active, not recruiting   44
  NCT02489890   II          CIK                                             Urinary bladder neoplasms                         Active, not recruiting   1,500
  NCT00185757   I           CIK                                             Multiple myeloma                                  Active, not recruiting   20
  NCT02485015   II          CIK + apatinib                                  Stomach neoplasms                                 Active, not recruiting   80
  NCT02490748   II          Radiofrequency ablation + CIK                   Cervical cancer                                   Active, not recruiting   10
  NCT02493582   II          CIK + apatinib                                  Adenocarcinoma of lung                            Active, not recruiting   400
  NCT02215837   II          Chemotherapy + DC--CIK                          Gastric cancer                                    Active, not recruiting   40
  NCT01924156   I/II        adenovirus-transfected DC + CIK                 Renal cell carcinoma                              Active, not recruiting   30
  NCT01898663   I/II        Adenovirus-transfected DC + CIK                 High-risk soft tissue sarcoma                     Active, not recruiting   30
  NCT02491697   II          DC--CIK + capecitabine monotherapy              Breast cancer                                     Active, not recruiting   400
  NCT02487693   II          Radiofrequency ablation + CIK                   Ovarian carcinoma                                 Active, not recruiting   50
  NCT02487992   II          CIK                                             Colorectal neoplasms                              Active, not recruiting   1,200
  NCT02693236   I/II        adenovirus-transfected autologous DC + CIK      Esophagus cancer                                  Active, not recruiting   30
  NCT02202928   II          DC--CIK + chemotherapy                          Colorectal cancer                                 Active, not recruiting   60
  NCT01956630   I/II        DC--CIK                                         Acute leukemia                                    Active, not recruiting   25
  NCT02688673   I/II        DC--CIK                                         Small-cell lung cancer                            Active, not recruiting   30
  NCT02678013   III         RFA + highly purified cytotoxic T lymphocytes   HCC                                               Active, not recruiting   210

These data were searched on 11 August, 2016 from the [ClinicalTrials.gov](ClinicalTrials.gov) (<http://www.clinicaltrials.gov>) using the word "cytokine-induced killer cells OR CIK."

In a first Phase I study, Schmidt-Wolf et al. demonstrated the safety and initial activity of CIK in therapeutic trials ([@B9]). In addition, CIK cells could be successfully expanded from patients treated with or without chemotherapy ([@B120]), so CIK cells were widely applied to treat various types of tumors including HCC, lung cancer, and gastrointestinal tumors (Table [1](#T1){ref-type="table"}).

Lee et al. reported that patients who received CIK immunotherapy after curative treatment for HCC had a 14-month median recurrence-free survival (RFS) benefit ([@B121]). The OS and cancer-specific survival were longer in the immunotherapy group compared to the control group. The ratio of AEs was significantly higher in the immunotherapy group (*P* = 0.002), but there was not a significant difference in the proportion of patients with serious AEs between groups (*P* = 0.15) (NCT00699816). It is worth noting that previous studies about CIK therapy for HCC showed significant benefits in preventing recurrence, but no significant survival gains ([@B122]--[@B124]). The difference of these results may be due to several aspects, such as the different intensified schedule of CIK, different cancer clinical stage or the non-standard quality of CIK cells (commercialized CIK cell compared to uncommercialized CIK cells). Lee et al. proved that adjuvant immunotherapy with activated CIK cells could increase the RFS and OS of patients who suffered with HCC ([@B125]) (NCT00699816). Furthermore, adjuvant CIK cells treatments were proved to be safe and effective for HCC treatment by several meta-analyses ([@B126]--[@B129]).

In 2012, a phase II clinical study showed that CIK immunotherapy could enhance the efficacy of conventional chemotherapy in patients with NSCLC ([@B130]). Furthermore, Chen et al. proved the MHC class I-related chain A (MICA) status was also associated with the outcome measures in CIK therapy for patients with gastric cancer, for the patients with high expression of MICA were more likely to benefit from CIK therapy ([@B131], [@B132]). In a phase II/III study, combined radiofrequency ablation with CIK has been reported to be a safe and effective treatment for CRLMs patients ([@B133]). Hereafter, many clinical studies were conducted to evaluate the efficacy of CIK/DC--CIK cell therapy for lung cancer, and all the results showed that CIK/DC--CIK was an effective therapy for lung cancer ([@B134]--[@B139]).

Many researches proved that CIK therapy was therapeutic for treatment of gastrointestinal tumors such as colorectal cancer and gastric cancer. In 2014, a meta-analysis in China showed that the combination of DC--CIK with chemotherapy could significantly improve the survival benefit, DFS rate, and overall response rate in patients with colon cancer. Furthermore, the number of CD4^+^ T cells was significantly increased in the DC--CIK + chemotherapy group ([@B98]). Zhao et al. reported that CIK cells could improve OS of metastatic colorectal cancer patients in a phase II clinical trial ([@B140]). Lin et al. showed that DC--CIK combined with chemotherapy could prolong PFS and OS in colorectal cancer patients compared to chemotherapy alone ([@B141]). Mu et al. summarized 17 eligible trials including 1,735 patients with gastric cancer in a meta-analysis, and they found that the combination of chemotherapy with CIK/DC--CIK significantly increased the OS rate and DFS rate, enhanced immune function, and reduced the AEs caused by chemotherapy ([@B97]). Kong et al. showed that the addition of CIK cells immunotherapy to standard chemoradiotherapy with temozolomide improved PFS but not OS in a phase III randomized trial of newly diagnosed glioblastoma in Korea ([@B142]) (NCT00807027).

The clinical outcome of cancer with different pathologic stages is different, but little is known about the achievable outcome of CIK cells in patients with different pathological stages of the tumor. Recently, Li et al. reported that combined CIK with conventional treatments could increase the survival rate of early-stage melanoma patients ([@B143]). So, whether the outcome of CIK is better in early-stage patient needs to be further studied.

As we have seen, most of the CIK registered clinical trials are restricted to Asian countries (64 trials), so it is difficult to completely evaluate the effects of CIK therapy over the world. Besides, the number of patients included in some clinical trials is also inadequate. So, more large-scale, grouped, controlled, multi-center, non-commercial clinical trials are required to confirm the immunotherapeutic effects of CIK in cancer treatment.

Conclusion and Prospects {#S6}
========================

In recent years, immunotherapy is considered to be a powerful pharmacological tool for the treatment of many malignancies ([@B144]). It is known that the expression of tumor antigens and MHC-I molecules are often downregulated or completely lost on tumor cells. Although the TILs could recognize specific antigens expressed by autologous tumor cells, this specific antigenicity is too low to achieve a high degree of antigenicity in therapeutic use ([@B120], [@B145]). What is more, the extremely low numbers of TIL cells and lymphokine-activated killer (LAK) cells also restrict their application. Compared to LAK cells, the CIK cells exhibit a relative higher proliferation rate and stronger antitumor activity. Especially for their non-MHC-restricted characteristic, CIK cells have a much broader antitumor spectrum. Antibody-based therapy and CAR-T cell therapy for cancer have been demonstrated to be one of the most successful and important treatment strategies, but there are still some details to be improved. One of the key challenges is to identify suitable antigens of tumors with explicit target genes. Unfortunately, the presence of intrinsic or acquired resistance has blunted the advantages of targeted therapies, the reason is partially due to the mutation or downregulation of specific antigen ([@B79]). The immune checkpoint blockade shows impressive clinical results, but the majority of patients are either resistant or relapse after therapy ([@B146]). Based on these data, optimal adoptive cellular immunotherapy (ACI) may require a portfolio of different treatment strategies.

As mentioned earlier, CIK cells are a heterogeneous population of CD3^+^ T lymphocytes, which maybe not only the biggest drawback but also the biggest advantage of this method. As a heterogeneous cell population, CIK cells are proved to contain different subpopulations and present a mixed T--NK phenotype. Until now, the precise subpopulation that is the most crucial and relevant to the clinical outcome and the exact pharmacological mechanism of how CIK kill tumor cells are still not completely understood. So, it is hard to precisely evaluate the effect of the CIK cell on immune response in cancer patients and hard to know why some clinical trials with CIK failed. Clearly, this uncertainty limits the clinical application of CIK. In contrast, as a heterogeneous cell population, CIK cells are able to kill heterogeneous tumor cells despite the tumor heterogeneity and antigen escape, which are major setbacks for the antibody-based and CART immunotherapy ([@B147]). And this may be the biggest advantage of CIK therapy. CIK cells therapy can improve the prognosis of cancer patients for its safety and decreased recurrence, so it would be the most effective treatment on residual cancer cells after conventional therapy.

Recently, much effort has been made to improve the antitumor activity of CIK cells and the recent findings of clinical applicability are reviewed in the paper. The promising outcomes have been made by CIK cells therapy combined with other therapies. But further research is still needed to optimize the procedure of CIK therapy. First, uniform culturing criteria should be formulated for CIK expansion. Second, more clinical trials need to be conducted with large-scale, controlled, grouped patients, including patients with different tumor stages and different cancer biomarkers. Only by doing these, can we figure out the tumor-killing mechanism of CIK cells and better evaluate their clinical efficacy.

More and more people realize that it is hard to cure cancer with only one drug or one therapeutic strategy. The combination of different drugs or therapies has already become a trend in treating heterogeneous tumors. As an effective ACI, CIK cells therapy provide a chance to prolong survival of cancer patients in clinical practice, and it is definitely worthy to spend more effort on it.

Author Contributions {#S7}
====================

XG, YM, and WJ conceived this study. XG and NG wrote the manuscript. HX and LX provided critical discussion in manuscript preparation. LX and WJ revised the manuscript. All the authors reviewed this manuscript.

Conflict of Interest Statement {#S8}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding**. This work was supported by the National Natural Science Foundation of China (Nos. 81402063, 31400913, 81601376, and 81402850), China Postdoctoral Science Foundation funded project (2016M), the Leading Disciplines Development Government Foundation of Shaanxi, China, University's key disciplines of molecular immunology, Doctoral research start-up fund project of Xi'an Medical University (Program Nos. 2015DOC07 and 2015DOC08). The Project was supported by the Natural Science Basic Research Plan in Shaanxi Province of China (No. 2017JM8086) and Scientific Research Program Funded by Shaanxi Provincial Education Department (15JK1636, 16JK1655).

[^1]: Edited by: José Mordoh, Fundación Instituto Leloir, Argentina

[^2]: Reviewed by: Estrella Mariel Levy, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina; Norberto Walter Zwirner, Institute of Biology and Experimental Medicine (IBYME-CONICET), Argentina

[^3]: ^†^These authors have contributed equally to this work.

[^4]: Specialty section: This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
